STOCKHOLM — A real-world analysis of retrospective data showed that administering more anti-VEGF injections over a 5-year time span to treat macular edema secondary to retinal vein occlusion (RVO) was ...

让科研和SCI论文成为临床工作的副产品。 导言： 为辅助课题选题及国自然基金撰写，熟悉最新研究热点和进展；尤其是协助找到最新的课题，我们每年都会就最近一年的临床科研的热门靶点进行解析。 本次解读“VEGF”相关的研究大数据分析。 更多医学文献 ...

Age-related macular degeneration (AMD) is the most common cause of central vision loss and blindness in adults. Wet AMD comprises 25% of all cases of AMD and is characterized by new blood vessel ...

4DMT Molecular Therapeutics Inc. is looking ahead to phase III as positive data continue to roll out for gene therapy candidate 4D-150 in wet age-related macular degeneration (AMD), with the results ...

Please provide your email address to receive an email when new articles are posted on . Visual acuity increased by 3 letters on average at year 1. By year 6, annual decreases led to a net loss of 4.6 ...

STOCKHOLM — Trial results are demonstrating positive findings for a single intravitreal injection gene therapy for patients with neovascular age-related macular degeneration (nAMD) who previously ...

The study found significant intra-group CMT reductions in the DEX-I group, with a higher percentage reduction than the ...

Both anti-VEGF and surgical treatments improve VA in AMD-related submacular hemorrhage, with no statistically significant difference between the two treatments. Anti-VEGF injections may be associated ...